Monday, August 27, 2001
Although Isis Pharmaceuticals Inc. has signed two large antisense deals
in recent months, ISIP maintains that the resurgence of antisense technology occurred last
year, when it presented preclinical diabetes data at the American Diabetes Association
meeting in San Antonio. These data, the company believes, finally convinced potential
partners that antisense has reached a stage where products may readily emerge.
Indeed, ISIP's data from the ADA meeting has led to two pharma
collaborations in the past three months. Under a May deal, ISIP granted Merck & Co.
Inc. (MRK, Whitehouse Station, N.J.) an exclusive license to its preclinical